| Biofilm-related disease |
46 |
| Recent advances in antibacterial applications of metal nanoparticles (MNPs) and metal nanocomposites (MNCs) against multidrug-resistant (MDR) bacteria |
23 |
| Ceftolozane/tazobactam: place in therapy |
19 |
| A successful history: probiotics and their potential as antimicrobials |
17 |
| Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control |
16 |
| Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America |
15 |
| Murepavadin: a new antibiotic class in the pipeline |
14 |
| Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs |
14 |
| Neurological complications of Zika virus infection |
13 |
| Management of toxoplasmosis in transplant recipients: an update |
12 |
| Risk of infection associated with anti-TNF-alpha therapy |
11 |
| Point prevalence study of antimicrobial use among hospitals across Botswana; findings and implications |
11 |
| Hand, foot, and mouth disease associated with coxsackievirus A10: more serious than it seems |
11 |
| Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence |
9 |
| Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward molecularly targeted' therapy |
9 |
| Improving the rates of Aspergillus detection: an update on current diagnostic strategies |
9 |
| Current research toward optimizing dosing of first-line antituberculosis treatment |
9 |
| Tebipenem, the first oral carbapenem antibiotic |
9 |
| Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies |
8 |
| Hepatitis C virus infection in children: How do we prevent it and how do we treat it? |
8 |
| Ozenoxacin: a review of preclinical and clinical efficacy |
8 |
| Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents |
8 |
| A multicenter point prevalence survey of antibiotic use in Punjab, Pakistan: findings and implications |
8 |
| Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children |
8 |
| Viral infections in the biologic therapy era |
8 |
| Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens? |
7 |
| Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications |
7 |
| HCV in Egypt, prevention, treatment and key barriers to elimination |
7 |
| Efficacy and safety of antimicrobial de-escalation as a clinical strategy |
7 |
| Factors determining phage stability/activity: challenges in practical phage application |
7 |
| Anti-infective treatment of brain abscess |
7 |
| Herpes simplex virus type 1 and Alzheimer's disease: link and potential impact on treatment |
7 |
| Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa |
6 |
| What we know and what we don't know about perinatal Zika virus infection: a systematic review |
6 |
| Ceftobiprole: drug evaluation and place in therapy |
6 |
| Strategies for the improvement of HCV testing and diagnosis |
6 |
| Expanding syphilis testing: a scoping review of syphilis testing interventions among key populations |
6 |
| Detection and treatment of Candida auris in an outbreak situation: risk factors for developing colonization and candidemia by this new species in critically ill patients |
6 |
| Perspective of community pharmacists about community-based antimicrobial stewardship programs. A multicenter cross-sectional study from China |
6 |
| The role of metabolomic markers for patients with infectious diseases: implications for risk stratification and therapeutic modulation |
6 |
| Non-prescription use of antibiotics among children in urban China: a cross-sectional survey of knowledge, attitudes, and practices |
6 |
| Stenotrophomonas maltophilia biofilm: its role in infectious diseases |
6 |
| Novel treatment strategies and drugs in development for cryptosporidiosis |
6 |
| Probiotic and cranberry supplementation for preventing recurrent uncomplicated urinary tract infections in premenopausal women: a controlled pilot study |
6 |
| Role of procalcitonin in bacteremic patients and its potential use in predicting infection etiology |
6 |
| Antibiotic stewardship in sepsis management: toward a balanced use of antibiotics for the severely ill patient |
6 |
| Monkeypox re-emergence in Africa: a call to expand the concept and practice of One Health |
6 |
| Biological challenges of phage therapy and proposed solutions: a literature review |
6 |
| Current anti-biofilm strategies and potential of antioxidants in biofilm control |
6 |
| Candidemia in the cancer patient: diagnosis, treatment, and future directions |
6 |
